Atopic Dermatitis: Perspectives and Attitudes of Adult Patients and Affected Child Caregivers Assessed by Focus Group
Abstract
Introduction: Important dimensions such as personal experiences, attitudes toward disease, its causes and treatments, are not fully addressed in clinical trials. Focus group (FG) has emerged as an interesting and valuable tool in clinical research complementing this gap. The aim of this qualitative research was to assess in both caregivers and patients dealing with atopic dermatitis (AD) their attitudes, personal experiences and perspectives toward the disease and its topical treatment as well as the impact in quality of life (QoL).
Material and Methods: For discussion sessions, 10 caregivers of children and 10 adult patients were recruited. Two sessions of FG took place with 3 main themes discussed: perspectives toward AD, topical treatments and the impact in QoL. All activities were recorded in video and the discussions and notes were then transcribed to a document, followed by transcripts analysis.
Results: The best descriptive feelings in the moment of diagnosis where “concern” (30%) and “quality of life” (30%) for caregivers and patients, respectively. The actual “positive” emotion or state of mind toward the disease was “overcoming” for caregivers (21%) and “control” for patients (17%). The main “negative or neutral” emotion was “fear” for caregivers (13%) and “resignation” for patients (18%), but when projecting to their child, “frustration” (19%) was the most mentioned. In relation to topical treatments, the mean global satisfaction of caregivers was high for tacrolimus (8.5/10), except in the item “price”. In the case of patients, corticosteroids received a better score (8.0/10), with exception for “tolerability/adverse effects”. Features like “preventive treatment with reduction of flares” and “free of cortisone” were important for both participants in an “ideal topical medicine” setting. All participants showed high levels of negative impact in their QoL due to AD, with 47% and 64.6% considering scores of “very much” and “a lot” of interference, respectively.
Conclusion: Qualitative studies in AD by FG are scarce and to our knowledge this is the first one gathering both adult patients and caregivers. The dimensions yielded by this approach are useful to complement data retrieved from clinical trials and to drive decisions from researchers and health authorities.
Downloads
References
Djulbegovic B , Guyatt GH. Progress in evidence-based medicine: a quarter century on. Lancet. 2017;390:415-23
Horwitz RI , Singer BH. Why evidence-based medicine failed in patient care and medicine-based evidence will succeed. J Clin Epidemiol. 2017;84:14-7
McNally NJ, Phillips DR , Williams HC. Focus groups in dermatology. Clin Exp Dermatol. 1998;23:195-200
Tarrant M, Warmoth K, Code C, Dean S, Goodwin VA, Stein K et al. Creating psychological connections between intervention recipients: development and focus group evaluation of a group singing session for people with aphasia. BMJ Open. 2016;6:e009652
Eichenfield LF, Ellis CN, Mancini AJ, Paller AS , Simpson EL. Atopic dermatitis: epidemiology and pathogenesis update. Semin Cutan Med Surg. 2012;31:S3-5
Chernyshov PV, Kaliuzhna LD, Reznikova AA , Basra MK. Comparison of the impairment of family quality of life assessed by disease-specific and dermatology-specific instruments in children with atopic dermatitis. J Eur Acad Dermatol Venereol. 2014
Carr WW. Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations. Paediatr Drugs. 2013;15:303-10
Thaci D, Reitamo S, Gonzalez Ensenat MA, Moss C, Boccaletti V, Cainelli T et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol. 2008;159:1348-56
Barbour RS. Making sense of focus groups. Med Educ. 2005;39:742-50
Peterson-Sweeney K. The use of focus groups in pediatric and adolescent research. J Pediatr Health Care. 2005;19:104-10
van Egmond S, Wakkee M, Droger M, Bastiaens MT, van Rengen A, de Roos KP et al. Needs and preferences of patients regarding basal cell carcinoma and cutaneous squamous cell carcinoma care: a qualitative focus group study. Br J Dermatol. 2018
Megna M, Patruno C, Balato A, Rongioletti F, Stingeni L, Balato N et al. An Italian multicentre study on adult atopic dermatitis: persistent versus adult-onset disease. Arch Dermatol Res. 2017;309:443-52
Fleischer AB, Jr., Abramovits W, Breneman D, Jaracz E , group USCtos. Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis. J Dermatolog Treat. 2007;18:151-7
Takahashi-Ando N, Jones MA, Fujisawa S , Hama R. Patient-reported outcomes after discontinuation of long-term topical corticosteroid treatment for atopic dermatitis: a targeted cross-sectional survey. Drug Healthc Patient Saf. 2015;7:57-62
Li AW, Yin ES , Antaya RJ. Topical Corticosteroid Phobia in Atopic Dermatitis: A Systematic Review. JAMA Dermatol. 2017
Aubert-Wastiaux H, Moret L, Le Rhun A, Fontenoy AM, Nguyen JM, Leux C et al. Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency. Br J Dermatol. 2011;165:808-14
Smith SD, Hong E, Fearns S, Blaszczynski A , Fischer G. Corticosteroid phobia and other confounders in the treatment of childhood atopic dermatitis explored using parent focus groups. Australas J Dermatol. 2010;51:168-74
Kosse RC, Bouvy ML, Daanen M, de Vries TW , Koster ES. Adolescents' Perspectives on Atopic Dermatitis Treatment-Experiences, Preferences, and Beliefs. JAMA Dermatol. 2018;154:824-7
Chung BY, Kim HO, Kim JH, Cho SI, Lee CH , Park CW. The proactive treatment of atopic dermatitis with tacrolimus ointment in Korean patients: a comparative study between once-weekly and thrice-weekly applications. Br J Dermatol. 2013;168:908-10
Ohtsuki M, Morimoto H , Nakagawa H. Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: Review on safety and benefits. J Dermatol. 2018
Wollenberg A, Reitamo S, Girolomoni G, Lahfa M, Ruzicka T, Healy E et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy. 2008;63:742-50
Glazenburg EJ, Wolkerstorfer A, Gerretsen AL, Mulder PG , Oranje AP. Efficacy and safety of fluticasone propionate 0.005% ointment in the long-term maintenance treatment of children with atopic dermatitis: differences between boys and girls? Pediatr Allergy Immunol. 2009;20:59-66
Peserico A, Stadtler G, Sebastian M, Fernandez RS, Vick K , Bieber T. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Br J Dermatol. 2008;158:801-7
Cury Martins J, Martins C, Aoki V, Gois AF, Ishii HA , da Silva EM. Topical tacrolimus for atopic dermatitis. Cochrane Database Syst Rev. 2015:CD009864
Hebert AA, Stingl G, Ho LK, Lynde C, Cappelleri JC, Tallman AM et al. Patient impact and economic burden of mild to moderate atopic dermatitis. Curr Med Res Opin. 2018:1-27
Bridgman AC, Eshtiaghi P, Cresswell-Melville A, Ramien M , Drucker AM. The Burden of Moderate to Severe Atopic Dermatitis in Canadian Children: A Cross-Sectional Survey. J Cutan Med Surg. 2018;22:443-4
Patel N , Feldman SR. Adherence in Atopic Dermatitis. Adv Exp Med Biol. 2017;1027:139-59
Salas M, Hughes D, Zuluaga A, Vardeva K , Lebmeier M. Costs of medication nonadherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature. Value Health. 2009;12:915-22
Lemstra M, Blackburn D, Crawley A , Fung R. Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Can J Cardiol. 2012;28:574-80
who.int [homepage na Internet]. 1; [consultado 2018 jul 10]. Disponível em: http://www.who.int/healthinfo/survey/whoqol-qualityoflife/en/
Grob JJ, Revuz J, Ortonne JP, Auquier P , Lorette G. Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. Br J Dermatol. 2005;152:289-95
Kiebert G, Sorensen SV, Revicki D, Fagan SC, Doyle JJ, Cohen J et al. Atopic dermatitis is associated with a decrement in health-related quality of life. Int J Dermatol. 2002;41:151-8
Kong TS, Han TY, Lee JH , Son SJ. Correlation between Severity of Atopic Dermatitis and Sleep Quality in Children and Adults. Ann Dermatol. 2016;28:321-6
Chamlin SL, Mattson CL, Frieden IJ, Williams ML, Mancini AJ, Cella D et al. The price of pruritus: sleep disturbance and cosleeping in atopic dermatitis. Arch Pediatr Adolesc Med. 2005;159:745-50
Brezinova E, Necas M , Vasku V. Quality of life and psychological disturbances in adults with atopic dermatitis in the Czech Republic. J Biol Regul Homeost Agents. 2017;31:227-33
Rabung S, Ubbelohde A, Kiefer E , Schauenburg H. [Attachment security and quality of life in atopic dermatitis]. Psychother Psychosom Med Psychol. 2004;54:330-8
Funakushi N, Yamaguchi T, Jiang J, Imamura S, Kuhara T, Suto H et al. Ameliorating effect of Yokukansan on the development of atopic dermatitis-like lesions and scratching behavior in socially isolated NC/Nga mice. Arch Dermatol Res. 2011;303:659-67
Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract. 2006;60:984-92
Pustisek N, Vurnek Zivkovic M , Situm M. Quality of Life in Families with Children with Atopic Dermatitis. Pediatr Dermatol. 2016;33:28-32
Holm EA , Jemec GB. Time spent on treatment of atopic dermatitis: a new method of measuring pediatric morbidity? Pediatr Dermatol. 2004;21:623-7
All articles in this journal are Open Access under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
